EDMONTON, Alberta–(BUSINESS WIRE)– #Canada–Australian eyewear retailer, Oscar Wylee announces their expansion into Canada, with their first store set to open in West Edmonton Mall, Alberta at the end of August 2021. This comes on the back of the eye…
Author: Business Wire
Boston Red Sox Legend David Ortiz to Star in new Zenni “PapiVision” Campaign
NOVATO, Calif.–(BUSINESS WIRE)– #BigPapi–Boston Red Sox legend David Ortiz is starring in Zenni’s latest “PapiVision” ad campaign launching exclusively on New England Sports Network.
DocSpace, Houston-Based Digital Health Startup, Raises $1.2 Million to Help Clinicians Build and Launch Independent Practices
HOUSTON–(BUSINESS WIRE)– #ClinicianEntrepreneurs–DocSpace, Houston-Based Digital Health Startup, Raises $1.2 Million to Help Clinicians Build and Launch Independent Practices
Harrow Health Acquires Ophthalmic Surgical Drug Candidate From Wakamoto Pharmaceutical Co., Ltd.
NASHVILLE, Tenn. & TOKYO–(BUSINESS WIRE)—- $HROW–Harrow Health, Inc. (NASDAQ: HROW), an ophthalmic‑focused healthcare company, today announced that it has entered into an agreement with Wakamoto Pharmaceutical Co., Ltd. to acquire the U.S. and Cana…
Alcon Reports Second Quarter 2021 Results
GENEVA–(BUSINESS WIRE)–Alcon Reports Second Quarter 2021 Results
VerkaziaTM (cyclosporine 0.1%) for the Treatment of Severe Vernal Keratoconjunctivitis is Now Reimbursed by Non-Insured Health Benefits (NIHB) Program
TORONTO–(BUSINESS WIRE)–VerkaziaTM (cyclosporine 0.1%) for the Treatment of Severe Vernal Keratoconjunctivitis is Now Reimbursed by Non-Insured Health Benefits (NIHB) Program
VerkaziaMC (cyclosporine à 0,1 %) est désormais remboursé par le Programme des services de santé non assurés (SSNA) pour traiter la kératoconjonctivite vernale grave
TORONTO–(BUSINESS WIRE)–Santen Canada Inc., filiale de Santen Pharmaceutical Co., Ltd. (« Santen »), société internationale œuvrant exclusivement dans le domaine de l’ophtalmologie, a annoncé aujourd’hui que VerkaziaMC (émulsion ophtalmique topique d…
Sonoma Pharmaceuticals Reports First Quarter 2022 Financial Results
WOODSTOCK, Ga.–(BUSINESS WIRE)–Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye, oral and, nasal …
Fabrinet Announces Fourth Quarter And Fiscal Year 2021 Financial Results
BANGKOK–(BUSINESS WIRE)– #Earnings–Fabrinet (NYSE: FN), a leading provider of advanced optical packaging and precision optical, electro-mechanical and electronic manufacturing services to original equipment manufacturers of complex products, today a…
LENSAR to Present at the H.C. Wainwright Ophthalmology Virtual Conference
ORLANDO, Fla.–(BUSINESS WIRE)–LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced that Nick Curtis, Chie…
Global Choroidal Neovascularization (Ophthalmology) Drug Development Market Report 2021: Stage of Development, Drug Target, Mechanism of Action, Route of Administration and Molecule Type – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Choroidal Neovascularization (Ophthalmology) – Drugs in Development, 2021” report has been added to ResearchAndMarkets.com’s offering. Choroidal Neovascularization (Ophthalmology) – Drugs in Development, 2021 provides an o…
Global Retinopathy (Ophthalmology) Drugs Development Market Report 2021: Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Retinopathy (Ophthalmology) – Drugs in Development, 2021” report has been added to ResearchAndMarkets.com’s offering. Retinopathy (Ophthalmology) – Drugs in Development, 2021 provides an overview of the Retinopathy pipelin…
Ocular Inflammation (Ophthalmology) Drugs Development Market Report 2021 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Ocular Inflammation (Ophthalmology) – Drugs in Development, 2021” report has been added to ResearchAndMarkets.com’s offering. Ocular Inflammation (Ophthalmology) – Drugs in Development, 2021 provides an overview of the Ocu…
Posterior Uveitis (Ophthalmology) Drugs Development Research Report 2021 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Posterior Uveitis (Ophthalmology) – Drugs in Development, 2021” report has been added to ResearchAndMarkets.com’s offering. Posterior Uveitis (Ophthalmology) – Drugs in Development, 2021 provides an overview of the Posteri…
NovaBay Pharmaceuticals Reports Second Quarter 2021 Financial Results
EMERYVILLE, Calif.–(BUSINESS WIRE)–NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) reports financial results for the three and six months ended June 30, 2021 and provides a business update. “Unit sales reached a new quarterly record as more peopl…
Harrow Health to Participate in Two Upcoming Virtual Investor Conferences
NASHVILLE, Tenn.–(BUSINESS WIRE)—- $HROW–Harrow Health, Inc. (NASDAQ: HROW), an ophthalmic-focused healthcare company, today announced that Mark L. Baum, Chief Executive Officer, and Andrew Boll, Chief Financial Officer, will participate in two upc…
Aerie Pharmaceuticals to Participate in the H.C. Wainwright Ophthalmology Conference
DURHAM, N.C.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glauco…
National Vision Holdings, Inc. Reports Second Quarter 2021 Financial Results; Raises Fiscal 2021 Outlook
DULUTH, Ga.–(BUSINESS WIRE)–National Vision Holdings, Inc. (NASDAQ: EYE) (“National Vision” or the “Company”) today reported its financial results for the second quarter ended July 3, 2021. Given the lack of comparability to the second quarter of fis…
Second Sight Medical Products Announces a New NIH Grant Supplement for Its Orion Study
LOS ANGELES–(BUSINESS WIRE)–Second Sight Medical Products, Inc. (NASDAQ: EYES) (the “Company” or “Second Sight”), a leading developer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individu…
Alcon to Launch TOTAL30 as the First-and-Only Monthly Replacement, Water Gradient Contact Lens
GENEVA–(BUSINESS WIRE)–Alcon to Launch TOTAL30 as the First-and-Only Monthly Replacement, Water Gradient Contact Lens